Avid Bio fielding client inquiries due to China bill; Oxford Bio wants to double its revenues

Wel­come to End­points News’ man­u­fac­tur­ing briefs, where we bring you es­sen­tial news on new builds, col­lab­o­ra­tions, re­calls and more.

Avid Bioser­vices has de­tect­ed an uptick in client in­ter­est in the wake of the Biose­cure Act and the No­vo-Catal­ent ac­qui­si­tion, CEO Nicholas Green said dur­ing the com­pa­ny’s first-quar­ter earn­ings call Mon­day, ac­cord­ing to an Al­phaSense tran­script. “It’s fair to say that there seems to be some cor­re­la­tion be­tween those events and the num­ber of op­por­tu­ni­ties that we’re see­ing ma­te­ri­al­ize at the ear­ly stage of dis­cus­sions at the be­gin­ning of this year,” Green said.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.